Medical articles
Rentosertib becomes the first end-to-end AI-designed drug to enter Phase III
In July 2026, Insilico Medicine launched a phase III trial involving 320 patients in 47 centers for the treatment of idiopathic pulmonary fibrosis based on its AI platform.